TrialKidney international2019

Plasma copeptin levels predict disease progression and tolvaptan efficacy in autosomal dominant polycystic kidney disease.

Ron T Gansevoort et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.